Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma.
Adult
Case-Control Studies
Contrast Media
Endoglin
/ genetics
Female
Gene Expression Regulation
Humans
Magnetic Resonance Imaging
/ methods
Male
Neovascularization, Pathologic
/ genetics
Neurofibromatosis 2
/ genetics
Neuroma, Acoustic
/ diagnostic imaging
Prognosis
Reference Values
Risk Assessment
Signal Transduction
CD105
endoglin
neurofibromatosis type 2
schwannoma growth rate
vestibular schwannoma
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
07
05
2019
accepted:
03
07
2019
pubmed:
18
7
2019
medline:
12
9
2020
entrez:
18
7
2019
Statut:
ppublish
Résumé
Neurofibromatosis type 2 (NF2) is an autosomal dominant, multiple neoplasia syndrome characterized by bilateral vestibular schwannomas (VSs). Endoglin is a proliferation-associated protein expressed in angiogenic endothelial cells. The aim of this study was to investigate endoglin expression in a series of NF2-associated VSs, as compared with a group of sporadic VSs. Using image analysis, vessel cross-sectional area (AA) and density (VD) were calculated from CD105 expression in 7 NF2-associated VSs and 14 size-matched sporadic VSs. There were no significant differences between NF2-associated VSs and sporadic cases in terms of AA (P = .28), or VD (P = .39). A positive correlation emerged between tumor growth rate (measured on contrast-enhanced MRI) and VD in the cohort of NF2-associated VSs (rho = 0.95, P = .05). Further investigations are needed to ascertain the feasibility of (a) measuring circulating endoglin levels to monitor tumor growth rate and (b) targeting tumor neoangiogenesis with anti-endoglin approaches in NF2-associated VS.
Sections du résumé
BACKGROUND
Neurofibromatosis type 2 (NF2) is an autosomal dominant, multiple neoplasia syndrome characterized by bilateral vestibular schwannomas (VSs). Endoglin is a proliferation-associated protein expressed in angiogenic endothelial cells. The aim of this study was to investigate endoglin expression in a series of NF2-associated VSs, as compared with a group of sporadic VSs.
METHODS
Using image analysis, vessel cross-sectional area (AA) and density (VD) were calculated from CD105 expression in 7 NF2-associated VSs and 14 size-matched sporadic VSs.
RESULTS
There were no significant differences between NF2-associated VSs and sporadic cases in terms of AA (P = .28), or VD (P = .39). A positive correlation emerged between tumor growth rate (measured on contrast-enhanced MRI) and VD in the cohort of NF2-associated VSs (rho = 0.95, P = .05).
CONCLUSIONS
Further investigations are needed to ascertain the feasibility of (a) measuring circulating endoglin levels to monitor tumor growth rate and (b) targeting tumor neoangiogenesis with anti-endoglin approaches in NF2-associated VS.
Substances chimiques
Contrast Media
0
Endoglin
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3612-3617Subventions
Organisme : University of Padova, Italy
ID : DOR1778819/17
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Kim BS, Seol HJ, Lee JI, et al. Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges. Neurosurg Rev. 2016;39(4):643-653.
Kontorinis G, Nichani J, Freeman SR, et al. Progress of hearing loss in neurofibromatosis type 2: implications for future management. Eur Arch Otorhinolaryngol. 2015;272(11):3143-3150.
Goutagny S, Bouccara D, Bozorg-Grayeli A, Sterkers O. Neurofibromatosis type 2. Rev Neurol (Paris). 2007;163(8-9):765-777.
Neff BA, Welling DB. Current concepts in the evaluation and treatment of neurofibromatosis type II. Otolaryngol Clin North Am. 2005;38(4):671-684.
Carlson ML, Breen JT, Driscoll CL, et al. Cochlear implantation in patients with neurofibromatosis type 2: variables affecting auditory performance. Otol Neurotol. 2012;33(5):853-862.
Ruggieri M, Praticò AD, Serra A, et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital. 2016;36(5):345-367.
Zanoletti E, Cazzador D, Faccioli C, et al. Multi-option therapy vs observation for small acoustic neuroma: hearing-focused management. Acta Otorhinolaryngol Ital. 2018;38(4):384-392.
Zanoletti E, Mazzoni A, d'Avella D. Hearing preservation in small acoustic neuroma: observation or active therapy? Literature review and institutional experience. Acta Neurochir. 2019;161(1):79-83.
Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett. 2018;16(1):687-702.
Marioni G, D'Alessandro E, Giacomelli L, Staffieri A. CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. J Oral Pathol Med. 2010;39(5):361-367.
Dourado KMC, Baik J, Oliveira VKP, et al. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood. 2017;129(18):2526-2536.
Zhang J, Zhang L, Lin Q, Ren W, Xu G. Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;9(7):7660-7671.
Zhang N, Chen J, Ferraro GB, et al. Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 2018;299(Pt B):326-333.
Ardern-Holmes S, Fisher G, North K. Neurofibromatosis type 2. J Child Neurol. 2017;32(1):9-22.
Committee on hearing and equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg. 1995;113:179-180.
Nicolè L, Cappellesso R, Sanavia T, Guzzardo V, Fassina A. MiR-21 over-expression and programmed cell death 4 down-regulation features malignant pleural mesothelioma. Oncotarget. 2018;9(25):17300-17308.
de Vries M, van der Mey AG, Hogendoorn PC. Tumor biology of vestibular schwannoma: a review of experimental data on the determinants of tumor genesis and growth characteristics. Otol Neurotol. 2015;36:1128-1136.
Goutagny S, Kalamarides M. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports. Neurochirurgie. 2018;64(5):370-374.
Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol. 2003;22:30-34.
Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
Gao X, Zhao Y, Stemmer-Rachamimov AO, et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc. Natl. Acad. Sci. U.S.A. 2015;112:14676-14681.
Sverak P, Adams ME, Haines SJ, et al. Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities. Otolaryngol Head Neck Surg. 2019;160(3):526-532.
Marioni G, Gaio E, Giacomelli L, et al. Endoglin (CD105) expression in head and neck basaloid squamous cell carcinoma. Acta Otolaryngol. 2005;125:307-311.
Marioni G, Marino F, Giacomelli L, et al. Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol. 2006;126(6):633-639.
Kasprzak A, Adamek A. Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy. Int J Mol Sci. 2018;19:3887.
Litwiniuk M, Niemczyk K, Niderla-Bielińska J, Łukawska-Popieluch I, Grzela T. Soluble endoglin (CD105) serum level as a potential marker in the management of head and neck paragangliomas. Ann Otol Rhinol Laryngol. 2017;126:717-721.
Gordon MS, Robert F, Matei D, et al. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014;20(23):5918-5926.